Vonoprazan: all 99 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Infection in United States AdolescentsNot yet recruitingNCT07860112Phase 2
• A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksRecruitingNCT07752407Phase 3
• Comparison of Rabeprazole and Vonoprazan in the Prevention of Post-endoscopic Variceal Ligation Ulcer in Patients With CirrhosisNot yet recruitingNCT07608536Phase 3
• Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori EradicationRecruitingNCT07439445Not applicable
• Vonoprazan Test for PPI Refractory GERDEnrolling by invitationNCT07437768Not applicable
• Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori InfectionRecruitingNCT07275827Phase 3
• The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant RecipientsRecruitingNCT07275632Phase 1/2
• Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled TrialRecruitingNCT07267260Phase 2
• Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori EradicationRecruitingNCT07242456Phase 2/3
• Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori InfectionNot yet recruitingNCT07040839Phase 4
• Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadicationRecruitingNCT06959368Phase 4
• Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEMRecruitingNCT06955520Not applicable
• A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 WeeksRecruitingNCT06953986Not applicable
• Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori EradicationRecruitingNCT06723197Phase 4
• Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive EsophagitisNot yet recruitingNCT06720610Phase 4
• Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux DiseaseRecruitingNCT06564246Phase 4
• Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal DissectionNot yet recruitingNCT06526455Phase 4
• Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp EradicationRecruitingNCT06349486Not applicable
• Triple Versus Quadruple Therapy for the Eradication of Helicobacter PyloriEnrolling by invitationNCT06299605Not applicable
• PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic UlcersRecruitingNCT05582174Phase 4
• A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy ParticipantsCompletedNCT06831344Phase 1Results posted
• A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice DailyCompletedNCT06391177Phase 1Results posted
• A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux DiseaseCompletedNCT06106022Phase 1Results posted
• A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy ParticipantsCompletedNCT05366738Phase 1Results posted
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux DiseaseCompletedNCT05343364Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)CompletedNCT05195528Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux DiseaseCompletedNCT04799158Phase 2Results posted
• A Study of Vonoprazan in Adults With Helicobacter PyloriCompletedNCT04753437Phase 1Results posted
• Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy ParticipantsCompletedNCT04729101Phase 1Results posted
• Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy ParticipantsCompletedNCT04545944Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori InfectionCompletedNCT04198363Phase 3Results posted
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori InfectionCompletedNCT04167670Phase 3Results posted
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive EsophagitisCompletedNCT04124926Phase 3Results posted
• A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) TabletCompletedNCT03808493Phase 1Results posted
• A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA TabletCompletedNCT03456960Phase 1Results posted
• Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory EvaluationCompletedNCT03116841Phase 4Results posted
• A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese ParticipantsCompletedNCT03085836Phase 1Results posted
• Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori InfectionCompletedNCT03050359Phase 3Results posted
• Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori InfectionCompletedNCT03050307Phase 3Results posted
• Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)CompletedNCT02954848Phase 3Results posted
• TAK-438 Bismuth Drug Interaction StudyCompletedNCT02892409Phase 1Results posted
• Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)CompletedNCT02743949Phase 2Results posted
• Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term SafetyCompletedNCT02679508Phase 4Results posted
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive EsophagitisCompletedNCT02388737Phase 3Results posted
• Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive EsophagitisCompletedNCT02388724Phase 3Results posted
• Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux DiseaseCompletedNCT07563491Not applicable
• Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) TabletsCompletedNCT07278349Phase 1
• A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksActive, not recruitingNCT06851559Phase 2
• Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux DiseaseCompletedNCT06778395Phase 4
• Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.CompletedNCT06642987Phase 1
• 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori EradicationCompletedNCT06576882Phase 3
• Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line EradicationCompletedNCT06514274Phase 4
• Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter PyloriCompletedNCT06414707Phase 3
• Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.CompletedNCT06412588Not applicable
• Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori InfectionCompletedNCT06250634Not applicable
• Vonoprazan for Helicobacter Pylori Eradication in AdolescentsCompletedNCT06162949Phase 3
• Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential TherapyCompletedNCT06156085Phase 4
• Potassium Copetitive Acid Blockers Efficacy in H.Pylori EradicationCompletedNCT06101420Phase 3
• High-dose Dual Therapy with Different Administration FrequenciesCompletedNCT05901051Phase 4
• One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIALStatus unknownNCT05728424Phase 3
• Optimization of Vonoprazan-based Dual Therapy for Helicobacter PyloriCompletedNCT05649540Phase 4
• A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori InfectionStatus unknownNCT05590286Phase 4
• Efficacy and Safety of Dual Therapy for Helicobacter Pylori EradicationCompletedNCT05469685Phase 4
• Vonoprazan Efficacy to Prevent Post Variceal Band Ligation UlcerCompletedNCT05227833Phase 3
• Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled StudyStatus unknownNCT05196945Phase 4
• 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid TherapyStatus unknownNCT05191888Phase 4
• The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter PyloriStatus unknownNCT05189444Not applicable
• Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)CompletedNCT05135793Phase 1
• Bismuth-containing Quadruple Therapy for Helicobacter Pylori EradicationCompletedNCT05049902Phase 4
• Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line EradicationCompletedNCT05014334Phase 4
• Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic HemostasisCompletedNCT05005910Early Phase 1
• Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori InfectionStatus unknownNCT04991584Not applicable
• Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori EradicationStatus unknownNCT04907747Phase 4
• Vonoprazan in Helicobacter Pylori Treatment an RCTCompletedNCT04901663Phase 4
• Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 DaysStatus unknownNCT04901117Phase 4
• The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or EsomeprazoleCompletedNCT04720781Not applicable
• Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy VolunteersCompletedNCT04568772Phase 1
• Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy ParticipantsWithdrawnNCT04558216Phase 1
• Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm FeaturesTerminatedNCT04028466Phase 4
• A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori GastritisStatus unknownNCT03908619Phase 4
• TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor ClarithromycinCompletedNCT02774902Phase 1
• TAK-438 - Safety, Blood Levels & Effects of Repeated DosesCompletedNCT02141711Phase 1
• Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese SubjectsCompletedNCT02141698Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male ParticipantsCompletedNCT02123953Phase 1
• Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male ParticipantsCompletedNCT02123927Phase 1
• A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive EsophagitisCompletedNCT01630746Phase 3
• A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin TherapyCompletedNCT01568398Phase 3
• A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) TherapyCompletedNCT01568385Phase 3
• Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. PyloriCompletedNCT01505127Phase 3
• Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux DiseaseCompletedNCT01474369Phase 3
• Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive EsophagitisCompletedNCT01459367Phase 3
• Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNCT01456260Phase 3
• Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNCT01456247Phase 3
• Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive EsophagitisCompletedNCT01452776Phase 3
• Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNCT01452763Phase 3
• Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNCT01452750Phase 3
• Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerCompletedNCT01452724Phase 3
• Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric UlcerCompletedNCT01452711Phase 3
• Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive EsophagitisCompletedNCT01452698Phase 3

← Vonoprazan overview